Amyris, Inc. (AMRS) Set to Announce Earnings on Wednesday
Amyris, Inc. (NASDAQ:AMRS) is scheduled to release its earnings data after the market closes on Wednesday, August 2nd. Analysts expect Amyris to post earnings of ($1.06) per share for the quarter.
Amyris (NASDAQ:AMRS) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($1.95) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.60. The firm had revenue of $13 million during the quarter, compared to analyst estimates of $32.30 million. Amyris’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.55) earnings per share. On average, analysts expect Amyris to post $-3.98 EPS for the current fiscal year and $-1.63 EPS for the next fiscal year.
Amyris, Inc. (NASDAQ AMRS) opened at 3.96 on Wednesday. The stock has a 50 day moving average price of $3.35 and a 200 day moving average price of $6.47. Amyris, Inc. has a one year low of $2.63 and a one year high of $18.15. The firm’s market capitalization is $78.43 million.
In other news, Director Patrick Y. Yang purchased 300,000 shares of Amyris stock in a transaction that occurred on Friday, May 19th. The shares were acquired at an average price of $0.29 per share, for a total transaction of $87,000.00. Following the transaction, the director now owns 153,000 shares of the company’s stock, valued at approximately $44,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.30% of the company’s stock.
Several analysts recently issued reports on the stock. HC Wainwright set a $15.00 price target on shares of Amyris and gave the stock a “buy” rating in a research report on Wednesday, June 7th. Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, ValuEngine lowered shares of Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $31.13.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.